Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

3(42.9%)

Phase 1

3(42.9%)

Phase 2

1(14.3%)

7Total

Early Phase 1(3)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07406724Phase 2Not Yet Recruiting

HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma

Role: lead

NCT07105176Phase 1Not Yet Recruiting

HS-IT101 Injection for Advanced NSCLC

Role: lead

NCT06941818Phase 1Enrolling By Invitation

HS-IT101 Injection in the Treatment of Advanced Melanoma

Role: lead

NCT06613152Early Phase 1Not Yet Recruiting

HS-IT201 Injection in the Treatment of Advanced Solid Tumors

Role: lead

NCT06342336Phase 1Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Role: lead

NCT05539768Early Phase 1Not Yet Recruiting

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Role: collaborator

NCT05505812Early Phase 1Not Yet Recruiting

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

Role: collaborator

All 7 trials loaded